Vanguard Group Inc. Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Vanguard Group Inc. lifted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 9.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,732,489 shares of the specialty pharmaceutical company's stock after acquiring an additional 151,808 shares during the period. Vanguard Group Inc. owned approximately 5.01% of KalVista Pharmaceuticals worth $16,684,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of KalVista Pharmaceuticals by 24.9% during the first quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company's stock worth $198,000 after purchasing an additional 2,677 shares in the last quarter. Bank of New York Mellon Corp grew its stake in KalVista Pharmaceuticals by 5.8% in the first quarter. Bank of New York Mellon Corp now owns 69,570 shares of the specialty pharmaceutical company's stock valued at $1,026,000 after acquiring an additional 3,838 shares during the period. MetLife Investment Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 103.8% in the first quarter. MetLife Investment Management LLC now owns 12,495 shares of the specialty pharmaceutical company's stock worth $184,000 after acquiring an additional 6,365 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of KalVista Pharmaceuticals by 16.3% in the first quarter. Rhumbline Advisers now owns 22,150 shares of the specialty pharmaceutical company's stock worth $326,000 after acquiring an additional 3,100 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of KalVista Pharmaceuticals by 2.6% during the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company's stock worth $22,757,000 after purchasing an additional 39,407 shares during the period.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV traded down $0.15 on Monday, hitting $11.74. 313,460 shares of the stock were exchanged, compared to its average volume of 765,791. The company has a market capitalization of $495.31 million, a PE ratio of -3.73 and a beta of 0.88. The business's fifty day moving average is $12.96 and its 200 day moving average is $11.22. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.21 and a 52 week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.09). Analysts predict that KalVista Pharmaceuticals, Inc. will post -3.05 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on KALV. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, February 14th. Needham & Company LLC restated a "buy" rating and issued a $35.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday.

Insiders Place Their Bets

In related news, major shareholder Venrock Healthcare Capital Par bought 39,680 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average price of $12.51 per share, with a total value of $496,396.80. Following the acquisition, the insider now owns 4,434,651 shares of the company's stock, valued at approximately $55,477,484.01. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Venrock Healthcare Capital Par purchased 39,680 shares of the company's stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average cost of $12.51 per share, with a total value of $496,396.80. Following the acquisition, the insider now owns 4,434,651 shares in the company, valued at approximately $55,477,484.01. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin L. Palleiko sold 22,802 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $14.11, for a total value of $321,736.22. Following the transaction, the chief financial officer now owns 187,315 shares in the company, valued at approximately $2,643,014.65. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 266,506 shares of company stock valued at $3,554,466 and sold 75,978 shares valued at $1,070,918. Company insiders own 12.30% of the company's stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.